XNAS · Healthcare · Medical Devices
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | Q1 2026 | -0.15 | -0.17 | -13.33% | $3.1M | ❌ Miss | -6.59% | +15.38% | — |
| 2026-03-11 | Q4 2025 | -0.14 | -0.14 | +2.14% | $3.3M | ✅ Beat | +10.09% | -0.92% | +3.67% |
| 2025-11-06 |
| Q3 2025 |
| -0.15 |
| -0.19 |
| -26.67% |
| $3.3M |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-14 | Q2 2025 | — | -0.26 | — | $6.3M | ❌ Miss | -4.66% | +2.33% | -40.47% |
| 2025-03-06 | Q4 2024 | 0.00 | -0.26 | -100.00% | $5.5M | ❌ Miss | +8.82% | +27.45% | +1.18% |
| 2024-11-14 | Q3 2024 | -0.44 | -0.33 | +25.00% | $5.9M | ✅ Beat | -7.05% | +14.88% | +7.83% |
| 2024-08-07 | Q2 2024 | -0.33 | -1.14 | -245.45% | $6.3M | ❌ Miss | +8.10% | +16.20% | +50.00% |
| 2024-03-07 | Q4 2023 | -0.28 | -0.66 | -135.71% | $5.9M | ❌ Miss | — | — | — |
Showing last 8 quarters.